PURPOSE The aim of this study was to evaluate whether low-dose anticholinergics combined with an α1-receptor antagonist would continue the effect of an alpha-blocker, decrease the side effects of anticholinergics, and improve the symptoms of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). MATERIALS AND METHODS Two hundred nine men with LUTS/BPH with storage symptoms (Int...

Therapeutic Class  Overview/Summary: The agents approved for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH) will be the focus of this review. The α-adrenergic blockers including, alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin, reduce smooth-muscle tone in the prostate and bladder neck decreasing lower urinary tract symptoms (LUTS) secondary to BPH. Alfuzo...

OBJECTIVES To evaluate the safety profile and efficacy of alpha1-adrenergic receptor blockers (A1Bs) currently prescribed for benign prostatic hyperplasia (BPH). DATA SOURCES A systematic literature search of MEDLINE, the Cochrane Database and the Food and Drug Administration Web site through December 2006 identified double-blinded, prospective, placebo-controlled trials, evaluating agents co...

Current testing for proarrhythmic potential of drugs relies on determining their effect on the QT interval of the ECG. Because QT prolongation is frequently associated with blockade of the human ether-à-go-go related gene (hERG) channel, the International Conference on Harmonization (ICH) S7B guideline recommends an hERG inhibition assay as the first proxy for identifying such potential risk. S...

A. Alpha adrenergic blockers (alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin) B. Hormonal manipulation (including finasteride, dutasteride, and dutasteride plus tamsulosin) C. Interstitial laser coagulation of the prostate (ILCP) D. Laser prostatectomy E. Laser based procedures including contact laser ablation of the prostate (CLAP), holmium laser procedures of the prostate (HoLAP, ...